Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Notes Payables (2016 - 2019)

Historic Notes Payables for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Q1 2019 value amounting to $18000.0.

  • Lineage Cell Therapeutics' Notes Payables fell 8500.0% to $18000.0 in Q1 2019 from the same period last year, while for Mar 2019 it was $18000.0, marking a year-over-year decrease of 8500.0%. This contributed to the annual value of $70000.0 for FY2018, which is 5394.74% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Notes Payables of $18000.0 as of Q1 2019, which was down 8500.0% from $70000.0 recorded in Q4 2018.
  • In the past 5 years, Lineage Cell Therapeutics' Notes Payables ranged from a high of $2.6 million in Q2 2017 and a low of $18000.0 during Q1 2019
  • In the last 5 years, Lineage Cell Therapeutics' Notes Payables had a median value of $123000.0 in 2017 and averaged $391812.5.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Notes Payables skyrocketed by 258947.37% in 2017, and later plummeted by 9530.33% in 2018.
  • Lineage Cell Therapeutics' Notes Payables (Quarter) stood at $95000.0 in 2015, then surged by 776.84% to $833000.0 in 2016, then crashed by 81.75% to $152000.0 in 2017, then crashed by 53.95% to $70000.0 in 2018, then crashed by 74.29% to $18000.0 in 2019.
  • Its Notes Payables was $18000.0 in Q1 2019, compared to $70000.0 in Q4 2018 and $70000.0 in Q3 2018.